

Editorial

Progress and development in many spheres of science often lead to a change in focus. The field of human hybridoma and antibody science, technology and engineering is no exception to this change. Now, like the transistor and the sliderule, hybridomas have become outmoded and replaced by new technology.

Thus as this journal enters its eighth year and heads towards the 21st Century, Volume 8, Number 1, sees a change in the title to *Human Antibodies*, reflecting the change in current status of the work and interest in this field. Human antibodies have many forms and functions and the new title of the journal reflects this, with the obvious focus on human antibodies, no matter what their form. However, hybridoma papers will still be considered for publication — there is no change there.

Poised for the next century, human antibodies will be a major component of the new biomedical therapy protocols utilizing recombinant products. This will not only affect the field of cancer research and treatment, but also autoimmunity, infectious diseases and the clinic. As this vital field develops and explores new territories we hope that *Human Antibodies* will be there too, to help 'spread the word'. Thank you for your continued support and interest in the journal.